MAPK3 and glioblastoma: A recent paper demonstrated that ERK1/2 phosphorylation in glioblastoma predicts the survival of patients following anti‐PD‐1 immunotherapy, highlighting ERKs as effective immunotherapy targets.[50] Investigating the role of the UA‐ERK1/2‐ULK1 axis and the usage of the small peptide Tat‐ERK156‐166 in different cell types would be intriguing.